Document is current
Any future updates will be listed below
-
Authors
Jordan, Karin https://orcid.org/0000-0001-9379-5938
Jordan, Berit
Burgt, Jennifer Vanden
Jahn, Franziska
-
Funding
Funding for this research was provided by:
Universitätsklinikum Heidelberg
- License Information
-
More Information
Article History
Received: 20 November 2024
Accepted: 5 June 2025
First Online: 24 June 2025
Declarations
:
: KJ reports personal fees as an invited speaker from Amgen, art tempi, Helsinn, Hexal, BMS, Merck, med update GmbH, Peer Voice, Mundipharma, Esteve, Roche, Shire (Takeda), Astra Zeneca and Astellas; personal fees for advisory board membership from Dompe, Stemline, AstraZeneca, BD Solutions, Hexal, Karyopharma, Voluntis, Abbot, Pfizer and Helsinn; royalties from Elsevier and UpToDate. BJ reports personal fees as an invited speaker from Alexion Pharmaceuticals, Argenx, Temmler, and UCB, and personal fees for advisory board membership from Alexion Pharmaceuticals and UCB. JV reports receiving consultancy fees from Helsinn Healthcare. FJ reports reports personal fees as an invited speaker from Amgen, Esteve and Astellas.
